All
Safe, effective hemostasis mandates
April 1st 2005New Orleans — Careful preoperative assessment to identify risk factors for increased perioperative bleeding, meticulous surgical technique to gain control of vessels and appropriate use of surgical adjuncts form the foundation for safe and effective hemostasis in dermatologic surgery, says David E. Kent, M.D., at the 63rd Annual Meeting of the American Academy of Dermatology.
Surgeon offers pearls for keloid tx
April 1st 2005Los Angeles — For stubborn keloids that do not respond to intralesional triamcinolone acetonide (Kenalog, Bristol-Myers Squibb), especially post-CABG sternal keloids, William V.R. Shellow, M.D., has successfully used methylprednisolone acetate (Depo-Medrol, Pharmacia & Upjohn), normally used by orthopedists for injecting joints.
Alternative treatments for alopecia areata
April 1st 2005Florence — Alopecia areata is a disease with important aesthetic implications that may affect the patient psychologically and socially, and treatment can be challenging, according to Ana Kaminsky, M.D., Ph.D., professor of dermatology, School of Medicine, University of Buenos Aires, Argentina.
Trial HSV-2 vaccines show promise
April 1st 2005Washington — Clinical studies have already demonstrated proof of concept for both prophylactic and therapeutic vaccines for herpes simplex virus (HSV)-2. Both types of HSV-2 vaccines are currently under development and the next few years should bring promising results, accordingto Lawrence R. Stanberry, M.D., Ph.D., chairman of the department of pediatrics and director of the Sealy Center for Vaccine Development at the University of Texas Medical Branch in Galveston.
Newer antibiotics potent weapons
April 1st 2005Aruba — Newer antibiotics with novel mechanisms of action offer activity against drug-resistant gram-positive organisms and are important additions to the dermatologist's therapeutic arsenal for treating cutaneous infections, according to Bernardo Vainrub, M.D., consultant in internal medicine and infectious diseases, Hospital de Clinicas, Caracas, Venezuela.
Clearance rates high, durable after 5-ALA PDT, study finds
April 1st 2005New Orleans — Results of a multicenter phase 4 study confirm the efficacy and safety of photodynamic therapy (PDT) using 20 percent 5-aminolevulinic acid (5-ALA) topical solution (Levulan Kerastick, DUSA) for the treatment of face and scalp non-hyperkeratotic actinic keratoses (AKs), according to Eduardo H. Tschen, M.D., who spoke at the 63rd Annual Meeting of the American Academy of Dermatology (AAD).
Petition prompts changes in AAD workforce initiative
April 1st 2005National report — Member discontent over the handling of the American Academy of Dermatology's (AAD) workforce initiative unveiled last fall is bringing about fundamental changes in the program — and perhaps in the decision-making process that governs such matters.
Does industry funding jeopardize objectivity?
April 1st 2005New Orleans — Recent research shows that the pharmacy and medical equipment industries influence a physician's practice, education and research, according to Jeffrey J. Meffert, M.D., program director of the dermatology program of the San Antonio Uniformed Services Health Education Consortium.
FDA board to protect patients, update docs
April 1st 2005Washington — Scorched by controversy over how it approves prescription drugs for the marketplace, the U.S. Food and Drug Administration (FDA) is preparing to establish an independent Drug Safety Oversight Board (DSB) to monitor FDA-approved pharmaceuticals and update physicians and patients when new information becomes available.
Too few antibiotics in pipeline
April 1st 2005A public health crisis is brewing, according to a white paper issued by the Infectious Diseases Society of America (IDSA), as two trends converge: the retreat of large and small pharmaceutical companies from antibiotic discovery and development, and the emergence of pathogens with resistance to an increasingly wide spectrum of currently approved antibiotics.
The Expanding Role of 5-FU in Dermatology (PDF)
April 1st 2005Recently, a group of leading dermatologists, clinical investigators, and dermasurgeons met to discuss the role of 5-fluorouracil (5-FU) in their practices. The experts discussed a new treatment paradigm for actinic keratosis (AK) and how it is changing. They also shared their personal experiences in using 5-FU innovatively to treat AK, while reducing inflammation and discomfort and improving compliance. In addition, the physicians reviewed the use of 5-FU in the treatment of several other dermatologic conditions, such aswarts and actinic cheilitis.
Ethics demands declining Superbowl tickets
March 1st 2005Dr. Dave and his friend Steve have known each other since ninth grade. They attended each other's weddings and have been together for many of life's good and bad moments. Steve also represents a publicly traded company that makes pharmaceutical products used by dermatologists.
Environmental problems impact derms
March 1st 2005New Orleans — Various environmental phenomena, such as the depletion of tropical rain forests, can affect human health — for instance, by eliminating the potential for lifesaving medications, says Peyton Weary, M.D., professor emeritus of dermatology at the University of Virginia and former president of the National Association of Physicians for the Environment.
Integration of alternative acne, rosacea interventions
March 1st 2005Aruba — Clear and unambiguous data demonstrate that therapeutic outcomes for patients with acne and rosacea can be enhanced by augmenting traditional care with more novel interventions, said Richard G. Fried, M.D., Ph.D., at the Caribbean Dermatology Symposium here.
Paradigm shift in Rosacea therapy
March 1st 2005Las Vegas — With recent modifications to the rosacea classification system and a greater understanding of the use of antibiotics as inflammatory mediators in rosacea treatment, Joseph Bikowski, M.D. of the Bikowski Skin Care Center, Sewickley, Pa., outlined a tiered approach to rosacea treatment at the Winter Dermatology Conference here.
Study of topical explores role of bacteria
March 1st 2005New Orleans — Bacteria play a role in rosacea development and that pathway should be further explored to develop novel agents to treat inflammatory lesions, says James Leyden, M.D., professor emeritus at the University of Pennsylvania School of Medicine, Philadelphia.
Ethics demands declining Superbowl tickets
March 1st 2005Dr. Dave and his friend Steve have known each other since ninth grade. They attended each other's weddings and have been together for many of life's good and bad moments. Steve also represents a publicly traded company that makes pharmaceutical products used by dermatologists.